Study of TNF-Antagonism in the Metabolic Syndrome (II)
Effects of Etanercept in Patients With the Metabolic Syndrome (II)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- MGH
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Hyperinsulinemia in the upper quartile of the non-diabetic population defined as >= 10 mU/mL (based on Framingham Data, oral communication, James Meigs, MD) or fasting glucose 110-126 mg/dL
Plus two of the following:
- Abdominal obesity defined by waist hip ratio > 0.90 for men and > 0.85 for women and BMI > 30 kg/m2
- Dyslipidemia including serum triglycerides >= 150 mg/dl or serum high density lipoprotein (HDL) < 0.9 mmol/L for men (35 mg/dL) and < 1.0 mmol/L (39mg/dL) for women
- Hypertension defined as blood pressure >= 140/90 or on medication
Exclusion Criteria:
- Age < 18 or > 60 years
- Body mass index (BMI) < 30 kg/m2
- Positive tuberculosis (purified protein derivative [PPD]) skin test (5mm induration or more) on screening
- Mycobacterial disease treated less than 6 months.
- Current or recurrent infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection.
- Therapy with glucocorticoid or immunosuppressant at time of recruitment or within past 3 months.
- Prior or concurrent cyclophosphamide therapy
- Use of a live vaccine 90 days prior to, or during this study.
- History of blood dyscrasia including any kind of anemia, thrombocytopenia, pancytopenia. Women with a reversible cause of anemia that has resolved will be eligible.
- Hemoglobin < 11 g/dl
- History of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers who will be eligible)
- History of organ transplantation
- HIV-positive status determined by HIV test at screening or known history of any other immuno-suppressing disease.
- Hepatitis B or hepatitis C infection detected at screening, lupus (SLE), history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
- Patients with known autoimmune or inflammatory conditions (excluding patients with stable, treated hypothyroidism)
- Severe comorbidities (diabetes mellitus requiring insulin, congestive heart failure (CHF) (EF<50% at baseline will be exclusionary) of any severity, myocardial infarction (MI), cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease
- Uncontrolled systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg
- Fasting blood glucose > 126 mg/dL
- Creatinine > 1.5
- Current use of insulin, any oral anti-hyperglycemic agents (including insulin sensitizing agents). Initiation of insulin, oral hypoglycemics, or insulin sensitizing agents during the study will result in discontinuation from the study.
- Initiation of statins, niacin, antihypertensive or fibrate therapy within 6 weeks of the study. Chronic use of fibrates, niacin, or antihypertensives for > 6 weeks prior to study initiation at a stable dose is not exclusionary, but chronic use of statins for > 6 months is exclusionary. Initiation of statins, fibrates, niacin or antihypertensive treatments during the study is not exclusionary but will be considered in the analysis (see Protection against risks).
- Positive pregnancy test or lactating females
- Women of child-bearing potential not currently using non-hormonal birth control methods including barrier methods (intrauterine device [IUD], condoms, diaphragms) or abstinence
- Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
- Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept
- Concurrent sulfasalazine therapy
- History of recent alcohol or substance abuse (< 1 year)
- Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient.
- History of non-compliance with other therapies
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
|
|
Aktiv komparator: Etanercept
|
50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
C-reactive Protein (CRP)
Tidsramme: 6 months
|
As a measure of C-reactive protein (CRP), which is an inflammatory marker, Log10 of the CRP at 6 months is reported
|
6 months
|
|
Interleukin-6 (IL-6)
Tidsramme: 6 months
|
6 month value of IL-6 (pg/mL)
|
6 months
|
|
Adiponectin
Tidsramme: 6 months
|
The ratio of circulating high molecular weight (HMW) adiponectin to total adiponectin ratio (HMW:total Adiponectin) at 6 months is reported.
|
6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Glucose Tolerance
Tidsramme: 6 months
|
Fasting glucose (mg/dL) at 6mo
|
6 months
|
|
Endothelial Function
Tidsramme: 6 months
|
Reactive Hyperemia Index (RHI) using peripheral artery tonometry (using Endo-PAT 2000).
Peripheral artery tonometry measures blood flow in the tip of the index finger at baseline and in response to vaso-occlusion (inflated blood pressure cuff).
The reactive hyperemia index is an index of vasodilation after occlusion compared to baseline.
A higher value indicates better vasoreactivity.
As this is a relatively new test, there are no thoroughly validated clinically utilized norms.
|
6 months
|
|
White Blood Cell (WBC) Count
Tidsramme: Baseline to 6 months
|
Change in WBC during study (WBC at six months minus WBC at baseline)
|
Baseline to 6 months
|
|
Cardiac Echo Ejection Fraction (EF)
Tidsramme: Baseline to 6 months
|
change in EF (6mo - baseline).
Please note that the value given is the absolute change in EF (which has units of percent), not the percent change in the variable.
|
Baseline to 6 months
|
|
Body Composition
Tidsramme: 6 months
|
6 month visceral adipose tissue (cm^2) - cross-sectional area of the visceral adipose tissue at the level of the 4th lumbar vertebrae was measured using single-slice abdominal computed tomography (CT) scan
|
6 months
|
|
Tumor Necrosis Factor (TNF) Receptor
Tidsramme: 6 months
|
Circulating concentrations of Tumor necrosis factor receptor 2 (TNFR2) at 6 months
|
6 months
|
|
Other Adipocytokines
Tidsramme: 6 months
|
circulating resistin at 6 months
|
6 months
|
|
Lipid Levels
Tidsramme: 6 months
|
total cholesterol (mg/dL) at 6 months
|
6 months
|
|
Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha
Tidsramme: 6 months
|
fold-change in subcutaneous adipose tissue expression of TNF-alpha (mRNA) after 6 months
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Steven K Grinspoon, MGH
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Glukosemetabolismeforstyrrelser
- Metaboliske sygdomme
- Sygdom
- Insulin resistens
- Hyperinsulinisme
- Syndrom
- Metabolisk syndrom
- Lægemidlers fysiologiske virkninger
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gastrointestinale midler
- Etanercept
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2006-P-001060
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .